2022
DOI: 10.1007/s12012-022-09754-6
|View full text |Cite
|
Sign up to set email alerts
|

An Improved Monkey Model of Myocardial Ischemic Infarction for Cardiovascular Drug Development

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 32 publications
0
2
0
Order By: Relevance
“…The distribution of the heart and coronary arteries in rhesus monkeys is highly similar to humans, making them one of the best choices for preparing models of MI ( 87 , 88 ). Studies generally construct MI models by ligating the left anterior descending coronary artery in 2-3 year old rhesus monkeys ( 88 , 89 ). One study has used the gene-edited pig heart and xenotransplant it into a baboon, managing the severe immune rejection that occurs with xenotransplants and keeping the baboon alive for more than two years ( 90 ).…”
Section: Animals Model Of MImentioning
confidence: 99%
“…The distribution of the heart and coronary arteries in rhesus monkeys is highly similar to humans, making them one of the best choices for preparing models of MI ( 87 , 88 ). Studies generally construct MI models by ligating the left anterior descending coronary artery in 2-3 year old rhesus monkeys ( 88 , 89 ). One study has used the gene-edited pig heart and xenotransplant it into a baboon, managing the severe immune rejection that occurs with xenotransplants and keeping the baboon alive for more than two years ( 90 ).…”
Section: Animals Model Of MImentioning
confidence: 99%
“…In addition to helping to discover the pathogenesis, animal models have also made great contributions to the development of medicines for treating human diseases. A case in point here is the cardiovascular drug is developed from a monkey model [ 11 ]. Similarly, researchers believe animal models are of positive significance for the development of COVID-19 clinical medicines.…”
Section: Introductionmentioning
confidence: 99%